Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects With Alagille Syndrome

NCT05543174 is registered in ClinicalTrials.gov with Takeda as lead sponsor.

NCT NCT05543174
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05543174 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of TAK-625 in the Treatment of Subjects With Alagille Syndrome
Lead sponsor
Takeda
Phase
Phase 3
Overall status
Completed
Start date
January 16, 2023
Completion date
July 25, 2025
Enrollment
7 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

alagille syndrome (algs)